[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585994":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":27,"overallOfficials":13,"centralContacts":32,"locations":42,"responsibleParty":59,"collaborators":61,"id":66,"slug":13,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":13,"enrollmentInfo":75,"targetDuration":13,"studyType":78,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":44,"whyStopped":13,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Changes in SUVmax before and after treatment","The uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value (SUV) on PET\u002FCT","Before treatment, 9 weeks after treatment, before surgery",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","SCREENING",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21],{"label":22,"type":23,"description":24,"interventionNames":25},"HER2 expression of PET imaging","EXPERIMENTAL","Evaluate the predict potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in breast cancer patients treated with ADC therapy",[26],"Radiation: HER2 expression of PET imaging",[28],{"type":29,"name":22,"description":30,"armGroupLabels":31,"otherNames":13},"RADIATION","Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in breast patients treated with ADC therapy",[22],[33,38],{"name":34,"role":35,"phone":36,"phoneExt":13,"email":37},"Xiaoyi Guo, PhD","CONTACT","010-88196495","15833916752@163.com",{"name":39,"role":35,"phone":40,"phoneExt":13,"email":41},"Yannan Yuan","01088197730","gcp_yuanyn@bjcancer.org",[43],{"facility":5,"status":44,"city":45,"state":13,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Beijing","100142","China","CN",{"type":50,"coordinates":51},"Point",[52,53],116.39723,39.9075,{"lat":53,"lon":52},[56,58],{"name":34,"role":35,"phone":57,"phoneExt":13,"email":37},"01088196495",{"name":39,"role":35,"phone":40,"phoneExt":13,"email":41},{"type":60,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR",[62,64],{"name":63,"class":6},"The Affiliated Hospital of Qingdao University",{"name":65,"class":6},"North Sichuan Medical College","100585994",false,"NCT06909604","Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy","Al18F-HER2-BCH PET\u002FCT to Predict Response in Breast Patients Treated With ADC Therapy","FHERAD","Inclusion Criteria:\n\n1. Aged ≥18 years old; ECOG 0 or 1;\n2. Patients with HER2 positive or low tumors;\n3. Receives neoadjuvant therapy\n4. Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;\n5. Life expectancy \\> 3 months -\n\nExclusion Criteria:\n\n1. Significant hepatic or renal dysfunction;\n2. Is pregnant or ready to pregnant;\n3. Cannot keep their states for half an hour;\n4. Refused to join the clinical research;\n5. Suffering from claustrophobia or other mental disorders;\n6. Any other situation that researchers considered it unsuitable to participate in the trial.","ALL","18 Years",{"count":76,"type":77},50,"ESTIMATED","INTERVENTIONAL",[15],"To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy",[82],"Breast Cancer",[84,85,86,87],"breast cancer","PET\u002FCT","HER2 expression","ADC therapy","2026-05-08",{"date":90,"type":91},"2026-05-13","ACTUAL",{"date":93,"type":91},"2025-01-01",{"date":95,"type":77},"2026-12-30",{"name":5,"class":6},1]